You are here


July 26, 2010
2010 International AIDS Conference, Vienna, Austria

The 2010 International AIDS Conference, held July 18–23 in Vienna, convened more than 20,000 AIDS researchers, policy makers and advocates. A number of MHRP staff attended and presented.

Dr. Merlin Robb, Deputy Director of Clinical Research participated in a panel discussion entitled, “Progress Toward an HIV Vaccine.” The panel discussed progress that's been made including the follow-up...

July 19, 2010
Microbicide Gel Shows Reduced Risk of HIV and Herpes Infection in Women

The MHRP applauds results announced today that the Center for the AIDS Program of Research in South Africa (CAPRISA) 004 trial showed that a vaginal microbicide gel could safely and effectively reduce the risk of heterosexual transmission of HIV from men to vulnerable women. 

The microbicide containing 1% tenofovir—an antiretroviral drug widely used in the treatment of HIV—was found to...

June 24, 2010
RV144: The Search for Correlates of Protection Begins

When the results of the RV 144 clinical trial were presented at the AIDS Vaccine Meeting in Paris in October 2009, the data suggesting modest vaccine efficacy were greeted with enthusiasm and also raised many questions about how this regimen was able to reduce the risk of HIV infection. 

Initial Laboratory Studies

As the clinical investigation phase of the effort ended,...

June 7, 2010
New Medical Male Circumcision Program Launched in Uganda

The Makerere University Walter Reed Project (MUWRP) partnered with the Mukono health authorities in Uganda to implement its first circumcision program. The newly renovated surgical theatre at the Kojja Health Center IV is now the primary circumcision clinic for the entire Mukono South area.

MUWRP held a ribbon-cutting ceremony on April 16, 2010 to officially launch the program....

May 26, 2010
Senior State Department Leadership Visit Nigeria Sites

On 26 May, Jack Lew, the U.S. Deputy Secretary of State, and Ambassador Goosby visited a medical centre at the Mogadishu Cantonment in Abuja.

Secretary Lew was impressed with the state of the Reference Laboratory and the Medical Center, which encompass a range of diagnostic and clinical services and provides an effective model for expanding capability to 20 other Nigerian Ministry of...

May 13, 2010
HIV Vaccine Awareness Day 2010

As we mark HIV Vaccine Awareness Day on May 18, I would like to acknowledge the 16,000 volunteers in Thailand, and the hundreds of scientists, health workers, trial staff and members of the U.S. Military HIV Research Program’s team that participated in the RV144 clinical trial.

The prime boost trial in Thailand marked a ‘yes we can’ moment for the field of HIV vaccine development. ...

April 14, 2010
2010 International Military HIV/AIDS Conference

The 2010 International Military HIV/AIDS Conference, co-hosted by the U.S. Department of Defense and the Tanzania People’s Defence Force, was held 12-15 April in Arusha, Tanzania. The theme of this year’s conference was “Building Sustainable Capacity and Leadership to Combat the Pandemic” and brought together representatives from nearly 70 militaries. 

Tanzanian President Jakaya Mrisho...

April 9, 2010
Presidential Commission for the Study of Bioethical Issues

President Barack Obama appointed COL Nelson Michael, the Director of MHRP, to the Commission for the Study of Bioethical Issues.

The Commission will advise the President on bioethical issues that may emerge from advances in biomedicine and related areas of science and technology. President Obama signed an Executive Order creating the new Presidential Commission for the Study of...

March 19, 2010
Early Study Shows MHRP Vaccine Candidate, MVA-CMDR, Safe and Immunogenic

MHRP scientists, working with NIAID, have developed an attenuated viral vector—modified vaccinia Ankara—vaccine candidate, MVA-CMDR (HIV-1 CM235 env/CM240 gag-pol). A Phase I study conducted in the U.S. and Thailand showed the vaccine was safe, well-tolerated and immunogenic. Study results, presented at the 2009 AIDS Vaccine Conference, suggest that MVA-CMDR is an ideal candidate for future...

March 18, 2010
Update on RV144

The Thai Phase III HIV vaccine clinical trial, also known as RV144, was the largest HIV vaccine study ever conducted and involved more than 16,000 volunteers in Thailand. This U.S. Army-sponsored HIV vaccine study showed that an investigational HIV vaccine regimen was safe and modestly effective (31.2% efficacy, mITT analysis) at reducing the rate of HIV infection compared to placebo.